GlassScriptPrepare for your visit
Samuel D Reid
Internal Medicine · Spartanburg, SC · NPI 1861463945
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$2,891.19
in general payments reported to CMS, 2019-2025 · $652 in 2025
The $652 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Who reported paying
General payments only, top 6 by amount.
- Amgen INC. $553.10
- Novartis Pharmaceuticals Corporation $341.15
- Astellas Pharma US INC $299.66
- Amarin Pharma, INC. $214.30
- Novo Nordisk INC $119.20
- Sanofi-Aventis U.S. LLC $117.45
Drugs and devices associated with these payments
Leqvio Veozah Repatha Otezla Evenity Voquezna Prolia Tymlos Intellis Adaptivestim Dexcom G6 Transmitter Tzield Rexulti
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Samuel Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/84738/samuel-d-reid